TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the TG Therapeutics' Third Quarter Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Tg Therapeutics Inc. (TGTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Woodline Partners Michael Rockefeller And Karl Kroeker | 2,565,322 | $60,002,882 | +81% | 0.5% |
| 2. | Soleus Capital Guy Levy | 2,534,540 | $59,282,891 | -31% | 4.59% |
| 3. | Opaleye Management James A. Silverman | 2,280,000 | $53,329,200 | 8.89% | |
| 4. | Deep Track Capital David Kroin | 1,725,000 | $40,347,750 | -40% | 1.27% |
| 5. | 683 Capital Partners Ari Zweiman | 1,135,000 | $26,547,650 | -19% | 2.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.13 | 100,000 | Officer, Director | 12,073,021 | 2023-08-11 | Filing | |
| $10.64 | 9,000 | Director | 201,848 | 2023-01-06 | Filing | |
| $7.04 | 50,000 | 12,878,185 | 2019-06-26 | Filing | ||
| $6.53 | 114,855 | Large Shareholder | 5,114,855 | 2015-02-17 | Filing | |
| $3.43 | 10,000 | Large Shareholder, Officer, Director | 7,839,471 | 2013-12-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.44 | 5,000 | Director | 100,195 | 2024-11-11 | Filing | |
| $30.20 | 25,000 | Director | 212,479 | 2024-11-11 | Filing | |
| $24.48 | 20,000 | Director | 224,098 | 2024-11-05 | Filing | |
| $16.87 | 16,348 | Director | 105,195 | 2024-06-20 | Filing | |
| $16.39 | 9,585 | Director | 99,293 | 2024-06-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,670,944 | $233,499,723 | 0% | |
| 2. | 10,768,163 | $183,920,222 | 0% | |
| 3. | 8,253,573 | $140,971,027 | 0% | |
| 4. | 3,385,245 | $57,819,985 | 0.06% | |
| 5. | 3,139,764 | $53,627,169 | 0.01% |
News See All
10 Stocks Set to Explode in 2025
As the Magnificent Seven continues to release earnings for the fiscal third quarter of 2024, investors are keen to see if the group can maintain their market leading position and exemplary performance...
14 Worst 52-Week High Stocks to Buy According to Short Sellers
The start of the US Federal Reserve cutting cycle ushers a new era in the investment world after one of the longest bull runs.
TG Therapeutics Inc (NASDAQ:TGTX) A Bull Case Theory
We came across a bullish thesis on TG Therapeutics Inc (TGTX) on ValueInvestorsClub by Bohr. In this article we will summarize the bulls' thesis on TGTX.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2024 Earnings Call Transcript
Operator: Greetings. Welcome to TG Therapeutics’ Conference Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the TG Therapeutics Conference Call and Webcast. At this time all participants are in a listen-only mode.
13 Best Biotech Stocks To Buy Under $20
In this article, we're going to take a look at 13 best biotech stocks to buy under $20.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript
TG Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.12. TG Therapeutics, Inc.
5 Best Growth Stocks Under $25
Boston, Massachusetts-based Flywire Corporation (NASDAQ:FLYW) is making a case as one of the best growth stocks to buy under $25 heading into 2024, going by its solid growth metrics.
11 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts.